News

Corbus Pharmaceuticals Begins Crucial Phase 1 Study for CRB-913

Corbus Pharmaceuticals Begins Crucial Phase 1 Study for CRB-913

Corbus Pharmaceuticals Starts Phase 1 Study for CRB-913

Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) has recently announced a significant advance in their clinical trials. The company has initiated the multiple ascending dose (MAD) portion of the Phase 1 study focusing on CRB-913, a novel treatment designed to combat obesity. This comes after the successful analysis of the single ascending dose (SAD) segment launched earlier.

Overview of the Phase 1 Trial

The MAD trial, which is set to be completed in the near future, aims to evaluate the safety and pharmacokinetics of CRB-913 when administered once daily for a week to healthy participants. The results from the earlier SAD study have laid a solid foundation for this next phase, indicating a promising outcome as the research progresses.

Key Findings from Initial Trials

Yuval Cohen, the CEO of Corbus, expressed optimism regarding the data collected thus far, stating that it shows a reassuring transition from preclinical to clinical settings. Notably, there have been no treatment-related neuropsychiatric events, even at higher doses than what initial models estimated would be necessary for efficacy.

Future Directions and Expectations

As the Company gears up for further investigations, they expect to transition to a Phase 1b dose-range finding study aimed at obese individuals later this year. This following study is expected to deepen the understanding of CRB-913’s efficacy. The overall timeline for completing the multiple ascending dose and subsequent studies is projected into a partnership with the upcoming quarters.

Understanding CRB-913 and Its Mechanism

CRB-913 works as an oral small molecule inverse agonist targeting the CB1 receptor, a hallmark mechanism historically linked to weight management. Unlike its predecessors which faced scrutiny over neuropsychiatric risks, CRB-913 is distinguished by its peripherally restricted design, aimed at reducing potential adverse effects while remaining effective.

The Commitment of Corbus Pharmaceuticals

Corbus is dedicated to innovating within the realms of oncology and obesity, utilizing well-known biological pathways to develop meaningful treatments. Their pipeline includes significant candidates such as CRB-701 and CRB-601, showcasing a broader commitment to tackling serious health issues as they emerge.

Collaborative Efforts and Recognized Goals

Part of the Company’s mission includes collaboration with clinical experts to refine their product offerings. The intention is to ensure that treatments like CRB-913 can provide substantial help to those struggling with obesity, paving the way for healthier futures.

Frequently Asked Questions

What is CRB-913?

CRB-913 is an oral small molecule designed as a CB1 inverse agonist aimed at treating obesity by minimizing neurological side effects.

What are the goals of the Phase 1 trial?

The Phase 1 trial aims to assess the safety, tolerability, and pharmacokinetics of CRB-913 in healthy volunteers before testing in obese individuals.

When will the results of the MAD portion be available?

Results from the MAD phase are anticipated as the trial is expected to complete soon, paving the way for further studies.

How does CRB-913 differ from other obesity treatments?

CRB-913 is designed to have reduced brain penetration, addressing concerns associated with previous drug classes that had neuropsychiatric risks.

Who can I contact for more information?

For inquiries, you can reach Sean Moran, the Chief Financial Officer of Corbus Pharmaceuticals via email.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 136

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 141

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 15

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 80

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading
Africa’s Digital Ownership Debate Gets More Serious

Updated Category News Views 107

Ownership was the uncomfortable word hanging over Cape Town on day two of Africa Tech Festival 2026, and frankly it should make investors sit up. Africa’s digital economy has no shortage of big promises, shiny AI demos or overseas executives talking about opportunity. The harder question is who funds the pipes, owns the data, makes the rules and actually keeps the...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 105

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 78

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 93

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 61

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 135

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading

Top 5 Most Recently Viewed Articles

Blue Moon Metals Secures C$60 Million for Strategic Growth

Updated Category News Views 164

Blue Moon Metals Announces Major Financing Initiative Blue Moon Metals Inc. (TSXV: MOON; OTCQX: BMOOF), based in Toronto, is embarking on an exciting new phase as the company has entered a letter agreement with key financial partners. These partners include Scotiabank and Canaccord Genuity Corp., who are playing a pivotal role as joint bookrunners in this financial...

Continue Reading
Theravance Biopharma Engages Investors at Upcoming Conference

Updated Category News Views 330

Theravance Biopharma's Upcoming Investor Conference Participation Theravance Biopharma, Inc. (NASDAQ: TBPH) is eager to actively engage with the investment community during a significant event. The company is set to take part in a Fireside Chat at an upcoming health conference, where it will discuss its ongoing projects and recent advancements in its pipeline. This event...

Continue Reading
Bright Green Partners with Benuvia for Raw Material Supply

Updated Category News Views 238

Bright Green Partners with Benuvia Operations Bright Green Corporation (Nasdaq: BGXX) has announced an important partnership through a letter of intent to provide its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a leading name in pharmaceutical cannabinoids. This collaboration highlights Bright Green's dedication and capability to...

Continue Reading
EHang's Progress and Financial Results: Navigating Change

Updated Category News Views 389

EHang Reports Its Third Quarter Financial Performance EHang Holdings Limited (NASDAQ: EH), a leader in advanced air mobility, has recently released its unaudited financial results for the third quarter. The company continues to strive towards maintaining its full-year revenue guidance of RMB500 million. In this article, we will highlight key operational and financial...

Continue Reading
Osisko Development Unveils Comprehensive Insights on Cariboo Gold

Updated Category News Views 258

Osisko Development Releases Technical Report for Cariboo Gold Project Osisko Development Corp. has taken a significant step in its journey to develop the Cariboo Gold Project by filing a comprehensive technical report. This report, prepared in line with the National Instrument 43-101 guidelines, highlights the feasibility study results for this promising site. The Cariboo...

Continue Reading